Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY24 results · Apr–Jun 2023
Torrent Pharmaceuticals reported revenue from operations of ₹2,591.00 crore (up 10.4% from Q1 FY23) and net profit of ₹378.00 crore (up 6.8% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,591.00 | 2,347.00 | +10.4% | 2,491.00 | +4.0% |
| Other income | 34.00 | 30.00 | +13.3% | 9.00 | +277.8% |
| Total income | 2,625.00 | 2,377.00 | +10.4% | 2,500.00 | +5.0% |
| Profit before tax | 531.00 | 532.00 | −0.2% | 433.00 | +22.6% |
| Net profit for the period | 378.00 | 354.00 | +6.8% | 287.00 | +31.7% |
| EPS, basic (₹) | 11.18 | 20.90 | not comparable | 8.48 | +31.8% |
| Net margin (%) | 14.6 | 15.1 | 11.5 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,121.00 | 1,933.00 | +9.7% | 1,920.00 | +10.5% |
| Other income | 11.00 | 29.00 | −62.1% | 26.00 | −57.7% |
| Total income | 2,132.00 | 1,962.00 | +8.7% | 1,946.00 | +9.6% |
| Profit before tax | 475.00 | 494.00 | −3.8% | 328.00 | +44.8% |
| Net profit for the period | 323.00 | 327.00 | −1.2% | 219.00 | +47.5% |
| EPS, basic (₹) | 9.55 | 19.35 | not comparable | 6.46 | +47.8% |
| Net margin (%) | 15.2 | 16.9 | 11.4 |
Consolidated
- Filed with BSE
- 07 Aug 2023, 18:01 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2023, 18:01 IST
- Board meeting
- 07 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE